Literature DB >> 22346324

Vorapaxar: targeting a novel antiplatelet pathway.

Younos Abdulsattar, Theologia Ternas, Danielle Garcia.   

Abstract

Entities:  

Year:  2011        PMID： 22346324      PMCID： PMC3278139     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  10 in total

Review 1.  Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.

Authors:  Jolanta M Siller-Matula; Julia Krumphuber; Bernd Jilma
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

2.  Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.

Authors:  Samuel Chackalamannil; Yuguang Wang; William J Greenlee; Zhiyong Hu; Yan Xia; Ho-Sam Ahn; George Boykow; Yunsheng Hsieh; Jairam Palamanda; Jacqueline Agans-Fantuzzi; Stan Kurowski; Michael Graziano; Madhu Chintala
Journal:  J Med Chem       Date:  2008-05-01       Impact factor: 7.446

Review 3.  Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.

Authors:  Tracy E Macaulay; Christopher Allen; Khaled M Ziada
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

4.  Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.

Authors:  Yukito Shinohara; Shinya Goto; Masaki Doi; Peder Jensen
Journal:  J Stroke Cerebrovasc Dis       Date:  2010-10-14       Impact factor: 2.136

5.  Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.

Authors:  Shinya Goto; Tetsu Yamaguchi; Yasuo Ikeda; Kenichi Kato; Hiroya Yamaguchi; Peder Jensen
Journal:  J Atheroscler Thromb       Date:  2010-02-03       Impact factor: 4.928

6.  Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.

Authors:  Richard C Becker; David J Moliterno; Lisa K Jennings; Karen S Pieper; Jinglan Pei; Alan Niederman; Khaled M Ziada; Gail Berman; John Strony; Diane Joseph; Kenneth W Mahaffey; Frans Van de Werf; Enrico Veltri; Robert A Harrington
Journal:  Lancet       Date:  2009-03-14       Impact factor: 79.321

7.  Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.

Authors:  David A Morrow; Benjamin M Scirica; Keith A A Fox; Gail Berman; John Strony; Enrico Veltri; Marc P Bonaca; Polly Fish; Carolyn H McCabe; Eugene Braunwald
Journal:  Am Heart J       Date:  2009-09       Impact factor: 4.749

8.  The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

Authors: 
Journal:  Am Heart J       Date:  2009-09       Impact factor: 4.749

9.  Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.

Authors:  Madhu Chintala; Kenji Shimizu; Masami Ogawa; Hiroya Yamaguchi; Masaki Doi; Peder Jensen
Journal:  J Pharmacol Sci       Date:  2008-12       Impact factor: 3.337

10.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  J Am Coll Cardiol       Date:  2007-08-14       Impact factor: 24.094
  10 in total
  4 in total

1.  Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?

Authors:  Xu Han; Marvin T Nieman
Journal:  Ann Transl Med       Date:  2018-02

Review 2.  Blood thinners and gastrointestinal endoscopy.

Authors:  Monjur Ahmed
Journal:  World J Gastrointest Endosc       Date:  2016-09-16

Review 3.  Platelets as Modulators of Cerebral Ischemia/Reperfusion Injury.

Authors:  David Stegner; Vanessa Klaus; Bernhard Nieswandt
Journal:  Front Immunol       Date:  2019-11-01       Impact factor: 7.561

Review 4.  Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?

Authors:  Simeng Li; Volga Tarlac; Justin R Hamilton
Journal:  Int J Mol Sci       Date:  2019-11-11       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.